Coordination of intratumoral immune reaction and human colorectal cancer recurrence

Cancer Research

Volumn 69, Issue 6, 2009, Pages 2685-2693

  Camus, Matthieu ^a,b,c   Tosolini, Marie ^a,b,c   Mlecnik, Bernhard ^a,b,c   Pages, Franck ^a,b,c   Kirilovsky, Amos ^a,b,c   Berger, Anne ^a   Costes, Anne ^a,b,c   Bindea, Gabriela ^a,b,c,d   Charoentong, Pornpimol ^d   Bruneval, Patrick ^a   Trajanoski, Zlatko ^d   Fridman, Wolf Herman ^a,b,c   Galon, Jérôme ^a,b,c  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; VASCULOTROPIN; VASCULOTROPIN A;

ADAPTIVE IMMUNITY; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CELL DENSITY; CELLULAR IMMUNITY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DISTANT METASTASIS; EFFECTOR CELL; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LYMPH NODE METASTASIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MOLECULAR DYNAMICS; NATURAL KILLER CELL; NATURAL KILLER T CELL; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; COLORECTAL TUMOR; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; TUMOR RECURRENCE; VASCULARIZATION;

CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; HUMANS; IMMUNOLOGIC MEMORY; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; T-LYMPHOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65549133014     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2654     Document Type: Article

References (47)

1. Finn OJ. Cancer immunology, N Engl J Med 2008;358: 2704-15.
2. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors. Immunity 1994;1:447-56.
3. Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon -γ-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-61.
4. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma, J Exp Med 2000;192:755-60.
5. van den Broek ME, Kagi D, Ossendorp E, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med 1996;184:1781-90.
6. Shankaran V, Ikeda H, Bruce AT, et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenidty. Mature 2001;410: 1107-11.
7. Zhou G, Lu Z, McCadden JD, Levitsky Hl, Marson AL. Reciprocal changes in tumor antigenicity and antigen- specific T cell function during tumor progression, j Exp Med 2004;200:1581-92.
8. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.
9. demente CG, Mihm MC, Jr., Bufalino K, Zurrida S, Collini P, Cascinelli N. Pronostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996;77: 1303-10.
10. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-43.
11. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348: 203-13.
12. Baier PK, Wimmenauer S, Hirsch T, et al. Analysis of the T cell receptor variability of tumor infiltrating lymphocytes in colorectal carcinomas. Tumour Biol 1998;19:205-12.
13. Dalerba P, Maccalli C, Casati C, Castelli C, Parmiani G. Immunology and immunotherapy of colorectal cancer. Crit Rev Oncol Hematol 2003;46:33-57.
14. + ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52:423-8.
15. + T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 1998; 58:3491-4.
16. + tumor-infiltrating lymphocytes in stage 111 colorectal cancer with and without microsatellite instability. Hum Pathol 2004;35:808-16.
17. Pages F, Berger A, Camus M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl j Med 2005;353:2654-66.
18. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313:1960-4.
19. Galon j, Fridman WH, Pages F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007;67:1883-6.
20. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
21. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Mat Rev Cancer 2003;3:401-10.
22. Smyth MJ, Godfrey DI, Trapani JA, A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001;2:293-9.
23. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity' and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
24. Kim R, Emi M, Tanabe K, Arihiro K, Tumor-driven evolution of immunosuppressive networks during malignant progression. Cancer Res 2006;66:5527-36.
25. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-74.
26. Khong HT, Restifo MP. Natural selection of tumor variants in the generation of "tumor escape" pheno-types. Nat Immunol 2002;3:999-1005.
27. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001;24:392-407.
28. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002;3:611-8.
29. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006;27: 195-201.
30. Sobin LH, Greene EL. Global TNM advisory group. Cancer 2004;100:1106.
31. Boulton SJ, Gartner A, Reboul J, et al. Combined functional genomic maps of the C. elegans DNA damage response. Science 2002;295:127-31.
32. Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. EASEB J 2002;16:61-71.
33. Sturn A, Quackenbush j, Trafanoski Z, Genesis: cluster analysis of microarray data, Bioinformatics 2002;18:207-8.
34. Shah S, Divekar AA, Hilchey SP, et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J Cancer 2005;117:574-86.
35. Tan TT, Coussens LM. Humoral Immunity, inflammation and cancer. Curr Opin Immunol 2007;19:209-16.
36. Doger FK, Meteoglu I, Tuncyurek P, Okyay P, Cevikel H. Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur Surg Res 2006;38:540-4.
37. Zheng S, Han MY, Xiao ZX, Peng JP, Dong Q. Clinical significance of vascular endothelial growth factor expression and neovascularization in colorectal carcinoma. World J Gastroenterol 2003;9:1227-30.
38. Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin Cancer Res 2007;13:2825-30.
39. Balkwill E, Coussens LM. Cancer: an inflammatory link. Mature 2004;431:405-6.
40. Moore Rj, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis. Nat Med 1999;5:828-31.
41. Voronov E, Shouval DS, Krelin Y, et al. IL-l is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci U S A 2003;100:2645-50.
42. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
43. Naumov GN, Akslen LA, Eolkman j. Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 2006;5:1779-87.
44. Vessella RL, Pantel K, Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 2007;6:1496-504.
45. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7: 834-46.
46. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007;450:903-7.
47. Xiang R, Lode HN, Gillies SD, Reisfeld RA. T cell memory against colon carcinoma is long-lived in the absence of antigen, J Immunol 1999;163:3676-83.